Mindpeak announces scanner agnostic CE-marked PD-L1 AI solution to support Lung Cancer Diagnosis
Mindpeak, European leader in Artificial Intelligence in Pathology, today announced the launch of a new CE marked deep le…
Mindpeak, European leader in Artificial Intelligence in Pathology, today announced the launch of a new CE marked deep le…
. Globale strategische Allianz zur optimalen Nutzung der Plasma-Safe-SeqS-Technologie von Sysmex QIAGEN wird in der…
Onkologische Fälle stellen Ärzte vor komplexe Anforderungen. Auf welche Ressourcen sollen sie zurückgreifen in einer Zei…
First HER2 directed therapy to show an improvement in overall survival for previously-treated metastatic gastric cancer…
9% of patients with HER2 mutant metastatic non-small cell lung cancer treated with ENHERTU achieved a tumor response Bre…
Results from the phase 2 DESTINY-CRC01 trial of Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZe…
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the Japanese Pharmaceuticals and Medical De…
GILUPI GmbH is pleased to announce its participation at the 2017 ACTC (Advances in Circulating Tumor Cells) congress. T…
The investors AURELIA, High-Tech Gründerfonds (HTGF), KfW, ILB, the - venture capital fund of the Sparkassen of Brandenb…
Die Investoren AURELIA, High-Tech Gründerfonds (HTGF), KfW, ILB, der Risikokapitalfonds der Sparkassen des Landes Brande…